%0 Journal Article
%T Treatment of benign maxillomandibular osteolytic lesions larger than 4 cm: A systematic review.
%A Colnot N
%A Savoldelli C
%A Afota F
%A Latreche S
%A Lupi L
%A Lerhe B
%A Fricain M
%J J Stomatol Oral Maxillofac Surg
%V 0
%N 0
%D 2024 May 30
%M 38823480
%F 2.48
%R 10.1016/j.jormas.2024.101933
%X <B>OBJECTIVE: </B>This systematic review aimed to assess the different treatments of benign maxillo-mandibular radiolucent bone lesions over 4 cm to propose a management algorithm.<BR><B>METHODS: </B>A literature search was conducted using MEDLINE/PubMed, Scopus, Google Scholar, Virtual Health Library databases, and gray literature. Randomized or non-randomized clinical trials and case series with 10 or more patients with a minimum follow up of 1 year, published in French or English until August 2023, were included. The risk of bias was assessed for all papers included.<BR><B>RESULTS: </B>Of 1433 records identified, 22 were included in this review, reporting data from 1364 lesions. Ameloblastoma was the most common lesion (51.22%) and mandible was the most common site (81.21%). Initial conservative treatment was prevalent (71.04%). Recurrence was higher after conservative (13.8%) than after radical treatments (6.5%). Multilocularity, cortical perforation, dental element preservation were linked to a higher recurrence risk.<BR><B>CONCLUSIONS: </B>This study has shown importance of understanding specific characteristics and recurrence risk in benign maxillomandibular osteolytic lesions. Multidisciplinary team approval, personalized approach based on lesion type and patient are crucial. The presence of at least one risk factor could lead to therapeutic decision. Despite limitations, the study informed lesion management and provided precise recommendations.